Heron Therapeutics is trading 7.1% down now at $0.31 after its August 10, 2026 earnings release reported a revenue miss and the company withdrew full-year guidance.
- Q2 revenue was $37.7 million versus a $42.13 million forecast.
- Potential generic CINVANTI competition, paused sales-force expansion, tighter spending, and a strategic-alternatives review clouded the outlook.
- HC Wainwright downgraded the shares from Buy to Neutral on August 11.